NCT04894305View on ClinicalTrials.gov

A Study of Ad26.COV2.S in Healthy Adults (COVID-19)

PHASE1CompletedINTERVENTIONAL

Enrollment

380

Participants

Timeline

Start Date

May 25, 2021

Primary Completion Date

December 8, 2021

Study Completion Date

December 8, 2021

Conditions

Healthy

Interventions

BIOLOGICAL

Ad26.COV2.S

Ad26.COV2.S will be administered as IM injection.

Trial Locations (1)

NZ 9728

PRA Health Sciences, Groningen

All Listed Sponsors

lead

Janssen Vaccines & Prevention B.V.

INDUSTRY